Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca disclosed that Chief Executive Officer Pascal Soriot received an allocation of 101,495 ordinary shares following the vesting of a long-term incentive award under the AstraZeneca Performance Share Plan. The award, originally granted in March 2021 with a three-year performance period and subsequent two-year holding period, vested at 88% of the maximum based on performance conditions, with shares delivered for nil consideration and a portion withheld to cover tax obligations.
The transaction, conducted outside a trading venue on 5 March 2026, increases Soriot’s beneficial interest in AstraZeneca stock and underscores the company’s continued reliance on performance-based equity to align executive compensation with shareholder returns. The fair market value used for tax purposes was set at 15,088 pence per share, reflecting the closing price on the last trading day before vesting and signalling the significant value of long-term incentives tied to AstraZeneca’s share performance.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £180.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
Spark’s Take on GB:AZN Stock
According to Spark, TipRanks’ AI Analyst, GB:AZN is a Outperform.
The score is driven primarily by strong underlying financial performance and a constructive earnings outlook (growth guidance and pipeline progress). This is tempered by valuation (P/E ~30), recent free-cash-flow variability, and technical signals that appear overextended despite the broader uptrend.
To see Spark’s full report on GB:AZN stock, click here.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing and commercialising prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Headquartered in Cambridge, U.K., the company markets innovative therapies in more than 125 countries, serving millions of patients worldwide.
Average Trading Volume: 2,695,814
Technical Sentiment Signal: Buy
Current Market Cap: £229.1B
Find detailed analytics on AZN stock on TipRanks’ Stock Analysis page.